Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by mining4dollarson Sep 09, 2013 1:47pm
231 Views
Post# 21727325

Re. 149 Patients..

Re. 149 Patients..
Well full results won't be released until Q1 2014, though there should be a fair amount of news flow leading up to it.  Expect another trial update within the next few weeks as they are required to do it quarterly.  Given the advanced stage of the trial at this point they may elect to include additional info, though I don't expect any efficacy(though it sure would be a pleasant surprise!)

As we near trial completion I'd also expect regional licensing talks to pick back up aggressively as a lot of risks have been mitigated by this advanced stage(assuming 149 patients have completed the full trial then safety concerns are essentially nil at this point) and it would obviously be cheaper to strike deals pre results than post, assuming efficacy is in line with phase 1.
Bullboard Posts